Business Update
April 16, 2024 – FUJIFILM Diosynth Biotechnologies today announced the decision to globally restructure its Small Scale Business Unit, that may result in up to 240 employees leaving the company. This impacts employees at its Teesside sites in the UK, and sites in College Station, Texas, Raleigh, North Carolina and Watertown, Massachusetts, in the US.
FUJIFILM Corporation continues to invest considerably in FUJIFILM Diosynth Biotechnologies, developing both its Small Scale and Large Scale facilities and expanding its global customer-centric network. Alongside measures taken to manage its operational and financial performance, FUJIFILM Diosynth Biotechnologies’ Small Scale Business Unit has been directly impacted by the short-term challenge of reduced venture capital investment in early-stage research projects, particularly in the cell and gene therapies market.
This restructuring is aligned to FUJIFILM Diosynth Biotechnologies’ strategic direction and intended to strengthen its Small Scale Business and elevate its operational and financial performance. It lays the groundwork for a solid foundation from which to build and unlock opportunity in the market, allowing the Company the ability to thrive and reinforcing its position as a leading competitor in the industry.
FUJIFILM Diosynth Biotechnologies is committed to our people and sites in the US and UK, and all the communities in which we operate.
US Media Contact:
Christine Jackman
FUJIFILM Holdings America Corporation
christine.jackman@fujifilm.com
914-261-4959
UK Media Contact:
Andy Ross
FUJIFILM Europe GmbH
+44 (0)7766 497949